FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205969970> ?p ?o ?g. }

• W4205969970 abstract "Abstract Background Hyperphosphorylated tau is a pathological hallmark of ∼45% of behavioural variant frontotemporal dementia (bvFTD). For this reason, hyperphosphorylated tau represents a promising treatment target for this population. Sodium selenate stimulates the PP2A enzyme, which directly dephosphorylates hyperphosphorylated tau. This Phase 1b, open‐labelled, study investigated sodium selenate as a disease‐modifying treatment for patients with bvFTD. Method Twelve patients with bvFTD were treated with sodium selenate (15mg tds) for twelve months. Participants underwent a cognitive and behavioural battery, MRI, lumbar puncture and safety assessments at screening, baseline, and at regular intervals following treatment commencement. Adverse events were monitored via diary cards between clinic visits. Result All 12 patients completed the study. Safety analysis found that sodium selenate was safe and well tolerated, with no study withdrawals. Commonly reported mild‐moderate adverse events were nail changes (n=6), muscles aches (n=4), headache, fatigue, hair loss and fall (n=3). Five patients reduced their dose to 10mg tds due to adverse events. No treatment‐related serious adverse events occurred. Analyses of efficacy data are ongoing. A mixed‐effects analysis showed an overall small but significant decline on cognition and behaviour, including total NUCOG score (b=‐0.18, 95% CI=‐0.28–0.08) Cambridge Behavioural Index (b=0.32, 95% CI=0.18‐0.46) and Carer Burden Scale score (b=0.1, 95% CI = 0.02‐0.18). Percentage change in whole‐brain volume from baseline to week 52 ranged from ‐0.26% to ‐6.51% (n=7 >‐1.8%, n=4 <‐1.8%). Plasma tau levels (n=6) did not change from baseline (3.73±0.26pg/mL) to week 52 (4.66±0.24pg/mL). CSF tau also showed no change from baseline (167.8±11.2pg/mL) to week 52 (156.1±2.49pg/mL). Although not significant, the directional changes are in line with the proposed mechanism of sodium selenate. Exploratory analyses of “responders” (brain volume change >‐1.8%, n=7) found no change in NUCOG total score (b=‐0.03, 95% CI ‐0.14‐0.07) or CBS score (b=‐0.05, 95% CI ‐0.04‐0.13) over time. Conclusion Sodium selenate is safe and well tolerated in patients with bvFTD. Exploratory analyses indicate it may reduce atrophy and halt cognitive decline in a subset of bvFTD patients. Sodium selenate should be further investigated as a potential treatment for bvFTD, and biomarkers to identify the subset of “responder” patients explored." @default.
• W4205969970 created "2022-01-25" @default.
• W4205969970 creator A5006499007 @default.
• W4205969970 creator A5015013868 @default.
• W4205969970 creator A5035778911 @default.
• W4205969970 creator A5059823463 @default.
• W4205969970 creator A5063419090 @default.
• W4205969970 date "2021-12-01" @default.
• W4205969970 modified "2023-10-17" @default.
• W4205969970 title "A phase 1b open label study of sodium selenate as a disease‐modifying treatment for behavioural variant fronto‐temporal dementia" @default.
• W4205969970 doi "https://doi.org/10.1002/alz.050979" @default.
• W4205969970 hasPublicationYear "2021" @default.
• W4205969970 type Work @default.
• W4205969970 citedByCount "0" @default.
• W4205969970 crossrefType "journal-article" @default.
• W4205969970 hasAuthorship W4205969970A5006499007 @default.
• W4205969970 hasAuthorship W4205969970A5015013868 @default.
• W4205969970 hasAuthorship W4205969970A5035778911 @default.
• W4205969970 hasAuthorship W4205969970A5059823463 @default.
• W4205969970 hasAuthorship W4205969970A5063419090 @default.
• W4205969970 hasBestOaLocation W42059699701 @default.
• W4205969970 hasConcept C126322002 @default.
• W4205969970 hasConcept C191897082 @default.
• W4205969970 hasConcept C192562407 @default.
• W4205969970 hasConcept C197934379 @default.
• W4205969970 hasConcept C2777223630 @default.
• W4205969970 hasConcept C2779134260 @default.
• W4205969970 hasConcept C2779483572 @default.
• W4205969970 hasConcept C2908647359 @default.
• W4205969970 hasConcept C553756173 @default.
• W4205969970 hasConcept C71924100 @default.
• W4205969970 hasConcept C99454951 @default.
• W4205969970 hasConceptScore W4205969970C126322002 @default.
• W4205969970 hasConceptScore W4205969970C191897082 @default.
• W4205969970 hasConceptScore W4205969970C192562407 @default.
• W4205969970 hasConceptScore W4205969970C197934379 @default.
• W4205969970 hasConceptScore W4205969970C2777223630 @default.
• W4205969970 hasConceptScore W4205969970C2779134260 @default.
• W4205969970 hasConceptScore W4205969970C2779483572 @default.
• W4205969970 hasConceptScore W4205969970C2908647359 @default.
• W4205969970 hasConceptScore W4205969970C553756173 @default.
• W4205969970 hasConceptScore W4205969970C71924100 @default.
• W4205969970 hasConceptScore W4205969970C99454951 @default.
• W4205969970 hasIssue "S9" @default.
• W4205969970 hasLocation W42059699701 @default.
• W4205969970 hasOpenAccess W4205969970 @default.
• W4205969970 hasPrimaryLocation W42059699701 @default.
• W4205969970 hasRelatedWork W1501867320 @default.
• W4205969970 hasRelatedWork W2059242980 @default.
• W4205969970 hasRelatedWork W2413479035 @default.
• W4205969970 hasRelatedWork W2990530825 @default.
• W4205969970 hasRelatedWork W313460363 @default.
• W4205969970 hasRelatedWork W4235339219 @default.
• W4205969970 hasRelatedWork W4236243970 @default.
• W4205969970 hasRelatedWork W4249661632 @default.
• W4205969970 hasRelatedWork W4255249625 @default.
• W4205969970 hasRelatedWork W2941673797 @default.
• W4205969970 hasVolume "17" @default.
• W4205969970 isParatext "false" @default.
• W4205969970 isRetracted "false" @default.
• W4205969970 workType "article" @default.